Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 15, 2018. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a regulatory disclosure of a securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ADSs via dividend reinvestment |
| Instrument | American Depositary Shares (ADSs) |
| Transaction Date | January 11, 2018 |
| Transaction Price | $36.84 per ADS |
| Total Volume | 443.929 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It discloses a routine transaction where dividends paid on January 11, 2018, were reinvested into ADSs held in the Company's US Deferred Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed by Mr. D E Troy, SVP & General Counsel, as part of the company's deferred performance share plan.
Key Facts for Investor Verification
- The transaction involved the acquisition of 443.929 ADSs at a price of $36.84.
- The acquisition was not a direct purchase but a reinvestment of dividends paid on January 11, 2018.
- The transaction was executed on the New York Stock Exchange.
- The filing does not provide any updated financial results or strategic outlook for GSK.